Bayer drug EU-Zulassung von Prostatakrebs-Medikament für weitere Indication Von dpa-AFX

BERLIN (dpa-AFX) – Der Pharma- und Agrarchemicalkonzern Bayer (ETR:) has met EU approval in another indication for its Medikament Nubeqa Prostatakrebs. This concerns the Unternehmen am Montag met. The information is based on the dates in the summer of the dates of the Phase III study Aranote zu Patients with metastasis, hormone-sensitive prostate glands and war become possible. Nubeqa (Wirkstoff Darolutamid) in combination with a hormone therapy that requires the radiological progression-free treatment (rPFS) in the statement of Placebo deutlich.

Nubeqa is available in many states in combination with hormone and chemotherapy in the treatment of patients with metastatic hormone-sensitive prostate gland disease (mHSPC). The treatment of patients with non-metastatic disease-resistant prostate treatment with a high degree of risk for the treatment of metastases (Hochriskiko-nmCRPC) is embedded. Der Umsatz des noch Young MedikamentWar 2023 was grim and lasted 2024 the Milliardenmarke knacken.